Background: Antiretroviral treatment (ART) reduces HIV infectiousness, but the effect of early ART on sexual behaviour is unclear.
Introduction
In 2015, results were published from the START (Strategic Timing of Antiretroviral Treatment Trial) 1, 2 and TEMPRANO 3 randomised trials, demonstrating that a strategy of immediate ART (regardless of CD4 cell count) for people with diagnosed HIV reduced serious morbidity and mortality compared to ART deferral. Guidelines that had previously set CD4 thresholds for ART initiation were changed to recommend ART initiation for all adults with HIV at any CD4 level. [4] [5] [6] US guidelines had already recommended such a strategy, primarily based on evidence from observational studies. 7 Prior to this conclusive evidence of the clinical benefit of early ART, results had been accumulating regarding the protective effect of ART on HIV transmission. Initially, a number of observational studies demonstrated a marked association between the viral load (VL) of an HIV-positive person and the risk of HIV transmission to an HIV-negative partner. [8] [9] [10] [11] [12] In 2011, unequivocal evidence came from the HPTN 052 randomised trial, which demonstrated that use of early ART for the HIV-positive partner of serodifferent couples was associated with a 96% reduction in transmissions to the HIV-negative partner. 13 Subsequently, the PARTNER 14 , PARTNER2 15 and Opposites Attract 16 prospective observational studies provided crucial information on transmission risk specifically through condomless sex (CLS), including anal CLS, among HIV serodifferent heterosexual and MSM couples. In each of these studies, there were no within-couple linked HIV transmissions during eligible follow-up in which couples reported CLS and the HIV-positive partner was virally suppressed on ART.
Together these studies have provided the necessary evidence for assurance that HIV-positive people on ART with undetectable VL cannot transmit HIV (Undetectable=Untransmittable; Prevention Access Campaign). 17 As knowledge regarding the protective effect of VL suppression on HIV infectiousness has been disseminated and publicized, and in particular since the 'Swiss Statement' in 2008, 18 it has been debated whether such knowledge impacts on sexual behaviour and patterns of condom use among people taking ART. [19] [20] [21] Initially the concern was that if viral suppression on ART led merely to a reduction in (rather than elimination of) HIV transmission risk, any increase by the HIV-positive individual in CLS with HIV-serodifferent partners (CLS-D) could partially negate the benefit of ART. 19, 20 Recent findings have provided reassurance on this point, demonstrating no transmission risk in this context. [14] [15] [16] However an increase in CLS-D associated with ART use may still be concerning in the context of sub-optimal ART adherence, infrequent VL monitoring, inaccurate knowledge of personal VL status 22 or poor knowledge of the importance of viral suppression, a key issue in early treatment. 23 Furthermore, any changes in patterns of CLS overall may have implications for transmission of other sexually transmitted infections (STIs). It is also conceivable that reductions in condom use among HIV-positive people may affect condom use among HIV-negative people with partners of unknown HIV status.
There is, to date, little compelling evidence that ART use leads to higher levels of condomless sex among people with HIV. Findings from some observational studies have suggested that, in some contexts or subgroups, condom use may be influenced by knowledge of viral suppression. [24] [25] [26] [27] [28] [29] However, in most studies, overall, levels of CLS-D were similar or lower among people on ART compared to those not on ART (or among people with undetectable compared to detectable VL). [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] Two randomised trials have provded data on this issue; 47, 48 neither supports the hypothesis that ART use leads to increased CLS-D.
However, it is important to reeavualte this association as patterns of sexual behaviour may have changed with increasing awareness of the protective effect of suppressed VL, paritcularly since publication of HPTN 052 in 2011. 13 Furtherore, now that the protective effect of viral suppression on HIV transmission is assured, it is necessary to consider measures additional to CLS-D, that capture sex with risk of HIV-transmission by accounting for viral suppression. 45, [47] [48] [49] When considering risk of other STIs, CLS overall is the most relevant measure.
We previously reported on sexual behaviour at enrolment in the START trial. 50 We now assess, separately among MSM and heterosexual individuals, the effect of a strategy of early ART compared to ART deferral on sexual behaviour in the first two years of follow-up, considering: CLS-D at month 12 (the pre-defined primary outcome), CLS, CLS-D with risk of HIV transmission, and other measures.
Methods

Study population
START was an open-label multicenter randomized trial enrolling 4684 HIV-positive people who had never taken ART and who had a CD4 count above 500 cells/μL, from April 2009 to December 2013. 1 Individuals were randomised to either start ART immediately (early ART) or to defer ART until occurrence of a CD4 cell count below 350 cells/μL or an AIDS event.
The primary endpoint was serious AIDS or non-AIDS morbidity or mortality. On May 15 th 2015, the Data and Safety Monitoring Board determined that the study question had been answered and recommended that ART be offered to all participants. Rate of the primary endpoint was lower in the immediate versus deferral arm [hazard ratio (95% CI): 0.43 (0.30, 0.62) p<0.001]. 2
Transmission risk behaviour study
Participants were asked to self-complete a transmission risk behaviour questionnaire at baseline, month 4, and every 12 months subsequently. Sexual activity (vaginal or anal sex) during the previous 2 months was ascertained for: men having sex with women; men having sex with men; women having sex with men. 50 All participants who had a risk behaviour questionnaire available within the first two years (at 4, 12, or 24 months) were included in this analysis. All information provided after 15 th May 2015 was excluded. Sexual behaviour measures (two month recall period) were derived at baseline and each follow-up point, including: (i) condomless sex with HIV-serodifferent (negative or unknown status) partners(s) (CLS-D); (ii) condomless sex (CLS); (iii) HIV transmission risk sex (CLS-D-HIV-risk) defined as CLS-D plus at least one of: not on ART; started ART <6 months ago; most recent VL>200c/mL; no VL in last 6 months. This last measure was intended to capture sex with a risk of HIV transmission. If a person having CLS-D was on ART, having started ART at least 6 months ago, and had most recent VL (measured within the past 6 months) ≤200 c/mL, then risk was assumed to be zero. Additional measures included: ≥2 CLS partners; ≥3 CLS partners; ≥2 CLS-D partners; ≥3 CLS-D partners; ≥2 times CLS-D; ≥10 times CLS-D; insertive CLS-D with ejaculation (men only); total number of CLS-D acts (see Table 3 footnote for details). Injection drug use transmission risk was defined as having injected drugs in the past two months and having shared needles or other equipment with someone who had negative/unknown HIV status. Transmission risk beliefs were beliefs related to whether a person using HIV treatment who had an undetectable viral load could pass on HIV to another person through unprotected sex. Responses of: "cannot" and "much less likely" were grouped together in contrast to: "a little less likely", "just as likely" and "more likely". The pre-specified primary outcome was CLS-D at month 12. Separate analyses were pre-specified for MSM, and heterosexual men and women (combined). 27 Some measures were considered only for MSM, due to low frequency among heterosexual participants.
Transmission risk behavior forms were updated early in recruitment. Information on CLS-D and CLS-D-HIV-risk was available from original and updated forms; information on all other outcomes was available only from the updated version. Participants were included in an analysis at a specific time point if the relevant behaviour questionnaire was available; treatment of missing values is described in the footnote of Table 3 .
Statistical methods
Baseline characteristics, and ART use and viral suppression over follow-up, were summarised according to gender/sexual orientation. Subsequent analyses were carried out separately for: MSM; heterosexual men and women combined. Sexual behaviour and attitude measures were For all comparisons participants were kept in their original randomised group.
Results
Of the 4684 HIV-positive people who were randomised, 112 (2.4%) were excluded from analysis as they had not completed a transmission risk questionnaire during the two year follow-up. Of the remaining 4572 participants there were 2562 MSM, 788 heterosexual men, and 1222 women. Baseline characteristics are shown in Table 1 .
Sexual behaviour at baseline
The baseline transmission risk questionnaire was completed by 4504 of 4572 (98.5%) participants (original version N=547, updated version N=3957). Prevalence of CLS in the past two months was 39.2%, 23.8%, and 28.1% among MSM, heterosexual men and women respectively; prevalence of CLS-D was 19.9%, 9.6% and 14.5% respectively. CLS-D-HIVrisk prevalence was identical to CLS-D prevalence (by definition, as no participants were on ART at baseline).
ART use and viral suppression over time
As of May 15 2015, of 4572 participants, all should have attended the months 4 and 12 visits, and 3673 (80.3%) should have attended the month 24 visit. Table 2 shows numbers completing the risk behaviour questionnaire by time point and the prevalence of ART use and VL ≤200 copies/mL, according to randomised arm and gender/sexual orientation. In the immediate arm, the proportion of participants who were on ART remained fairly stable from month 4 to month 24, at around 96-98%. Correspondingly, the prevalence of VL ≤200 copies/mL increased rapidly from baseline to month 4, with some further increase to month 24. In the deferred arm, the proportion on ART increased steadily over follow-up (as more individuals reached eligibility for ART initiation), mirrored by an increase in prevalence of viral suppression. Table 3 shows sexual behaviour by randomised arm and time point for: (A) MSM and (B) heterosexual men and women.
Comparison of sexual behaviour at month 12 between randomised arms
Among MSM, prevalence of CLS-D at month 12 (the primary outcome) was similar in the immediate and deferred arms: 12.6% versus 13.1% [difference: -0.4%, 95% CI (-3.1%, 2.2%), p=0.75 Chi-squared test]. The prevalence of CLS, ≥2 CLS-D partners, ≥3 CLS-D partners, ≥2 times CLS-D, >10 times CLS-D and insertive CLS-D with ejaculation at month 12 did not differ between the arms, nor did number of CLS-D acts among the subgroup diagnosed >3 months ago who reported CLS-D at baseline. The prevalence of CLS-D-HIVrisk at month 12 among MSM was much lower in the immediate versus deferred arms: 0.2% versus 11.0% [difference: -10.7%, 95% CI (-12.5%, -8.9%), p>0.001], due to the far higher prevalence of VL suppression on ART in the immediate arm.
Among heterosexual men and women there was some evidence that CLS-D at month 12 was higher in the immediate versus deferred arm: 10.8% versus 8.3% [difference: 2.5% 95% CI (-0.1%, 5.2%), p=0.062, Chi-squared test]. A similar pattern was apparent for ≥2 times CLS-D: 7.1% versus 5.2%, [difference: 1.9%, 95% CI (=0.3%, 4.1%), p=0.089, Chi-squared test].
Prevalence of CLS, ≥2 CLS partners, ≥2 CLS-D partners, and insertive CLS-D with ejaculation did not differ by arm at month 12, nor did number of CLS-D acts among those diagnosed >3 months ago who reported CLS-D at baseline. Although prevalence of CLS-D was somewhat higher in the immediate versus deferred arm among heterosexual individuals, the prevalence of CLS-D-HIV-risk at month 12 was much lower in the immediate arm: 0.6% vs 7.7% [difference:-7.0%, 95% CI (-8.8%, -5.3%), p<0.001, Chi-squared test], due to viral suppression on ART.
Comparison of randomised arms according to baseline factors: CLS-D at month 12
The odds ratio (95% CI) of CLS-D at month 12 for the immediate versus deferred strategy was 0.96 (0.76, 1.22) for MSM and 1.34 (0.98, 1.82) for heterosexual men and women (the latter adjusted for gender). (Figure 1 ). Among MSM, there was no evidence that the intervention effect on CLS-D varied across subgroups. Among heterosexual men and women, the intervention effect (higher CLS-D at month 12 in the immediate versus deferred arm) was greater among participants aged <40 years (p=0.035 for interaction). Table 3 and Figure 2 show the prevalence of sexual behaviour measures by time point and randomised arm. The additional baseline estimates exclude participants diagnosed for less than three months.
Time since randomisation and sexual behaviour
Prevalence of CLS-D fell from revised baseline to month 4 in both arms, among MSM and heterosexuals. By month 24, prevalence had increased back towards the revised baseline level for MSM in both arms, and for heterosexuals in the immediate arm. For heterosexuals in the deferred arm, prevalence of CLS-D continued to fall throughout follow-up, resulting in higher CLS-D prevalence in the immediate versus deferred arm at month 24 [9.3% vs 5.6%, difference: 3.7%, 95% CI (1.0%, 6.4%), p=0.007, Chi-squared test].
Patterns in CLS-D prevalence during follow-up were assessed formally in two multivariable logistic GEE models using data from the 4, 12 and 24 month time points. Among MSM (N=7003 observations), there was no interaction between randomised arm and study time point (p=0.24). In a model without an interaction term, CLS-D did not differ by randomised (Table 3 and Figure 1c ). As expected this decrease was particularly dramatic in the immediate ART group, resulting in substantial differences in CLS-D-HIV risk between randomised groups at months 12 and 24.
Transmission risk beliefs
At month 12, participants in the immediate arm were more likely than those in the deferred arm to indicate a belief that a person on HIV treatment with undetectable VL cannot, or is much less likely, to transmit HIV when having unprotected sex: 48 (Table   3 ). Similar differences between arms were apparent at month 24 (Table 3) .
For both MSM and heterosexuals, the proportion of participants who indicated this belief in a strong protective effect of viral suppression tended to increase over time from baseline in both arms. However evidence that this belief was more likely with later calendar time was relatively weak. There was no trend in proportions reporting this belief over calendar time of questionnaire completion among MSM or heterosexuals in the immediate arm at month 12 or 24. In the deferred arm, there was some evidence of a trend at month 24 
Risk behaviour related to injection drug use
Discussion
Among MSM, compared to ART deferral until a CD4<350 cells/μL or AIDS, a strategy of immediate ART had no impact on prevalence of HIV-serodifferent condomless sex (CLS-D) over the subsequent two years, or on related measures of frequency of such sex or partner numbers. Among heterosexual men and women, the immediate ART strategy resulted in modestly higher prevalence and frequency of HIV-serodifferent condomless sex at 12 and 24 months compared to deferred ART. Among both groups, the immediate ART strategy resulted in a substantial reduction in prevalence of HIV-transmission risk sex by month 12, as the vast majority of participants in this arm had viral suppression on ART and were therefore classified as no risk for HIV transmission, regardless of sexual behaviour.
CLS-D was the pre-defined primary endpoint in this study; this endpoint remains important for understanding the impact of early ART on condom use with serodifferent partners.
However, the two additional endpoints are the most relevant for HIV and STI transmission.
CLS-D-HIV-risk best captures HIV transmission-risk sex by accounting for viral suppression
on ART, now known to be a critical factor in preventing transmission. CLS best captures risk of transmission or acquisition of other STIs, for which HIV-serostatus of partners, ART and HIV viral load are not relevant. These results illustrate the profound impact of early ART on HIV-transmission risk sex, which was less than 1% in the immediate ART arm by month 12 (compared to 11% and 8% for MSM and heterosexuals respectively in the deferred ART arm) and was continued at this low level to month 24. Even though the immediate ART strategy resulted in a small increase in CLS-D among heterosexual participants at months 12 and 24, the impact of this was far outweighed by the high levels of viral suppression in this arm, which protected against HIV-transmission regardless of CLS-D. Even a very substantial increase in CLS-D would not have overturned the benefit conferred by early ART. Of note, this analysis suggested a benefit only from month 12, because the definition of CLS-D-HIVrisk required ART to have been started at least 6 months previously to confer protection from transmission. This was based on data from the Partners Prep study which indicated a reduced but residual transmission risk persisting during the first 6 months of ART, due to incomplete viral suppression in blood and genital compartments. 23 In practice, and with newer ART drugs, viral suppression and subsequent protection may be attained at an earlier stage after ART initiation. But also of note, the difference between arms in CLS-D-HIV-risk attenuated from month 12 to month 24, and this would continue to occur as more individuals in the deferral arm started ART. In terms of STI transmission risk, the strategy of early ART resulted in a modest increase in prevalence of CLS among heterosexual individuals at year two only. However, less than 2% of heterosexual participants reported more than one CLS partner in the recall period. Risk of STI acquisition and transmission may be less concerning in this context. Incidence of bacterial STIs was not assessed in START.
Two previous randomised trials have assessed the impact of ART on sexual transmision risk; 47, 48 neither supported the hypothesis that ART use leads to increased condomless sex. In the SMART trial (2002) (2003) (2004) (2005) (2006) , the prevalence of 'high-risk behaviour' (CLS-D or injecting risk behaviour) was similar compared between the continuous ART and CD4-guided episodic ART arms. 47 Among the subgroup who were not on ART at baseline, there was a reduction in high-risk behaviour in the first two years in the continuous compared to episodic ART arm.
More recently ,in the TEMPRANO-ANRS12136 trial of immediate versus deferred ART initiation (2008-2012), the proportion of participants reporting CLS-D was similar when compared between randomised arms at year one. 48 Many observational studies have assessed the association between ART and sexual behaviour among people with diagnosed HIV, including two meta-analyses 29, 32 and some studies in low/middle income countries. 41, 43, 45 The vast majority found no association of ART use or viral suppression with CLS-D, or found ART was in fact associated with lower levels of CLS-D. A few studies reported different findings overall, or in specific subgroups or analyses. Among sexually active women in the US Women's Interagency HIV Study (1996-2001), consistent condom use was less likely to be reported after ART initiation compared to pre-ART, in some adjusted models. 24 A small Australian study of HIV-serodifferent MSM couples (2001) (2002) (2003) found higher levels of anal CLS-D among couples for whom the positive partner had suppressed VL. 25 The Swiss HIV Cohort Study (2007-2009) found evidence of higher levels of CLS-D with stable partners among participants who were virally suppressed compared to those not on ART. 26 In a French study (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) , in more recent years, ART use and suppressed VL were associated with CLS-D among HIV-diagnosed heterosexual men with steady partners. 27 In the UK ASTRA study (2011-12), prevalence of CLS-D among MSM on ART was higher for those with self-reported undetectable VL compared to those without. 28 Finally, a subsidiary analysis in one of the aforementioned meta-analyses found that an undetectable VL was associated with slightly higher sexual risk-taking. 29 Therefore previous literature suggested that, in some contexts, condom use may be influenced by knowledge of viral suppression, but the effect may be modest, and evidence is relatively Indeed there was evidence of significant variation in transmission risk beliefs by recruitment setting, which differed for MSM and heterosexuals. MSM from high income countries were more likely than those from low/middle income countries to express belief in a strong protective effect of viral suppression, whereas for heterosexuals there was some evidence of the opposite effect (belief more prevalent in low/middle income settings). The trial was carried out over a period of considerable change with regard to scientific evidence available on this issue, and publicity surrounding it, and these complex trends are likely to reflect this.
Increasing emphasis on the "U=U" message 17 may be leading to further changes in transmission risk beliefs and patterns of condom use; it is likely that the full effect of the current research evidence is yet to be apparent.
Among MSM, in both the immediate and deferred treatment arms, CLS-D prevalence fell from randomization to months 4 and 12, and subsequently increased back towards the revised baseline levels by year two. Among heterosexual participants, a similar but less marked decline in CLS-D occurred from revised baseline to month 4. Other studies have reported on temporary reductions in sexual risk for MSM following HIV diagnosis, 53, 54 and so a similar pattern may have occurred for those individuals in START who were newly diagnosed at trial entry. In addition, for all participants, trial participation and regular contact with health care professionals and services, may have had a moderating effect on levels of condomless sex.
Limitations of this study include the possibility of error or bias arising from self-reported sexual behaviour and incomplete or missing questionnaires, though 12 month response rates were high and similar between randomised arms, and questionnaires were self-completed.
Participation in a trial with repeated monitoring of behavioural outcomes may have influenced condom use or it's reporting. The measure of HIV-transmission risk sex assumes that the latest VL is applicable to the entire two-month recall period.
In conclusion, a strategy of early ART did not impact on levels of serodifferent condomless sex among MSM and resulted in a small increase among heterosexual individuals. However in both groups, the strategy had a substantial favourable impact on HIV transmission risk behaviour at one year and is therefore likely to result in a marked reduction in new HIV infections in the initial period. The modest increase in condomless sex among the heterosexual group suggests the importance of continuing to monitor sexual behaviour as ART use expands, in order to understand any impact on other sexually transmitted infections.
Patterns of condomless sex may have changed with increasing promotion of the U=U message since the START trial was conducted. *112 of 4684 randomised participants were not included in the sub-study as they did not complete the transmission risk behavior questionnaire at any of the three follow-up time points (months 4, 12 and 24). ~Missing values: n=57 for time since diagnosis; n=8 for baseline VL. BL=baseline CLS-D = Condomless sex with HIV negative (or unknown status) partner(s). CLS-D-HIV-risk= HIV transmission risk sex defined as CLS-D plus at least one of: not on ART; started ART <6 months ago; most recent VL>200c/mL; no VL in last 6 months $ Baseline 2 estimates exclude those diagnosed less than 3 months before completing the baseline questionnaire, who may be reporting pre-diagnosis sexual behavior. P values by Chi-squared tests or Fisher's exact test (F), or Mann-Whitney U tests for CLS-D acts. ^p value for change from baseline in number of CLS-D acts in subset.
For each analysis denominators are all participants who submitted a transmission risk behavior questionnaire at that time point. # Denominators are larger for CLS-D and CLS-D-HIV-risk as these measures could be derived from both versions of the risk behavior questionnaire; other measures could be derived only from the updated version.
Missing values: For binary measures of CLS, CLS-D, CLS-D-HIV-risk, among those who completed the relevant transmission risk behaviour questionnaire, missing data were assumed to be the absence of the behaviour (<5% cases). For transmission risk beliefs, missing data were excluded. For number of CLS-D acts see below. ~Number of CLS-D acts was approximated from grouped data as follows: 2-10 times approximated as 6; 11-30 times approximated as 20; More than 30 times approximated as 40.
Number of CLS-D partners was approximated from grouped data as follows: 3-5 women approximated as 4; more than 5 women approximated as 8.
For those who had CLS-D, if number of CLS-D acts was missing or was less than the number of CLS-D partners, the value for number of CLS-D partners was used, if this was missing, number of CLS-D partners and number of CLS-D acts was set to one. £ Subset is those who reported CLS-D at baseline and who had been diagnosed with HIV for at least 3 months at baseline. For denominators by time point and p values comparing randomised arms, see Table 3 . 
CLS-
